Video navigation menu

• Interindividual variability in response to statins 0:09
• Targeting inflammation to lower residual risk 2:14
• Reducing hsCRP is as important as reducing LDL-c to lower vascular events 3:55
• The NLRP3 inflammasome - central to the postulated mechanism underlying inflammation in CV disease 4:50
• Targeting the IL-1beta - IL-6 pathway in two large ongoing clinical trials 5:51
• The fundamental question: 'Will lowering inflammation lower CV risk in the absence of change in LDL-c level?' 6:46